Success Metrics

Clinical Success Rate
100.0%

Based on 16 completed trials

Completion Rate
100%(16/16)
Active Trials
0(0%)
Results Posted
6%(1 trials)

Phase Distribution

Ph phase_4
8
50%
Ph phase_1
1
6%
Ph phase_2
2
13%
Ph phase_3
5
31%

Phase Distribution

1

Early Stage

2

Mid Stage

13

Late Stage

Phase Distribution16 total trials
Phase 1Safety & dosage
1(6.3%)
Phase 2Efficacy & side effects
2(12.5%)
Phase 3Large-scale testing
5(31.3%)
Phase 4Post-market surveillance
8(50.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

16 of 16 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

16

all time

Status Distribution
Completed(16)

Detailed Status

Completed16

Development Timeline

Analytics

Development Status

Total Trials
16
Active
0
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 11 (6.3%)
Phase 22 (12.5%)
Phase 35 (31.3%)
Phase 48 (50.0%)

Trials by Status

completed16100%

Recent Activity

0 active trials
Showing 5 of 16
completedphase_2

Four Different Experimental Drug Regimens to Standard of Care for the Treatment of Symptomatic Outpatients With COVID-19

NCT04532931
completedphase_3

Effectiveness and Safety of Intermittent Preventive Treatment for Malaria Using Either Dihydroartemisinin-piperaquine or Artesunate-amodiaquine in Reducing Malaria Related Morbidities and Improving Cognitive Ability in School-aged Children in Tanzania

NCT03640403
completedphase_4

Test Efficacy Study on the Recommended Antimalarial Drugs in the Democratic Republic of the Congo

NCT06076213
completedphase_4

Safety and Efficacy of Recommended Antimalarial in the Democratic Republic of the Congo

NCT04618523
completedphase_3

Artemisinin-Based Antimalarial Combinations and Clinical Response in Cameroon

NCT01845701
View all 16 trials

Clinical Trials (16)

Showing 16 of 16 trials
NCT04532931Phase 2

Four Different Experimental Drug Regimens to Standard of Care for the Treatment of Symptomatic Outpatients With COVID-19

Completed
NCT03640403Phase 3

Effectiveness and Safety of Intermittent Preventive Treatment for Malaria Using Either Dihydroartemisinin-piperaquine or Artesunate-amodiaquine in Reducing Malaria Related Morbidities and Improving Cognitive Ability in School-aged Children in Tanzania

Completed
NCT06076213Phase 4

Test Efficacy Study on the Recommended Antimalarial Drugs in the Democratic Republic of the Congo

Completed
NCT04618523Phase 4

Safety and Efficacy of Recommended Antimalarial in the Democratic Republic of the Congo

Completed
NCT01845701Phase 3

Artemisinin-Based Antimalarial Combinations and Clinical Response in Cameroon

Completed
NCT02940756Phase 4

Efficacy and Safety of Artemisinin-based Combination Treatments in the Democratic Republic of the Congo

Completed
NCT00119132Phase 2

Effectiveness of Intermittent Preventive Treatment for Malaria in Children

Completed
NCT00119145Phase 4

Kintampo Trial of Combination Therapy for Malaria

Completed
NCT02242799Phase 1

Dolutegravir Interactions With Artemisinin-based Combination Therapies

Completed
NCT00852423Phase 3

Safe and Efficacious Artemisinin-based Combination Treatments for African Pregnant Women With Malaria

Completed
NCT01231113Phase 3

Efficacy,Safety and Tolerability of Dihydroartemisinin-Piperaquine for Uncomplicated Malaria in Pregnancy in Ghana

Completed
NCT01755559Phase 4

Efficacy of Three ACTs for the Treatment of Falciparum Malaria in Maradi Niger

Completed
NCT00808951Phase 4

In Vivo and in Vitro Efficacy of Antimalarial Treatments in Children in Burkina Faso

Completed
NCT01017770Phase 4

Artemether-lumefantrine (AL) Versus Artesunate + Amodiaquine (ASAQ) for the Treatment of Uncomplicated Falciparum Malaria in Burkina Faso

Completed
NCT01213433Phase 4

Amodiaquine+Artesunate for Uncomplicated Malaria Treatment

Completed
NCT01374581Phase 3

Impact of Artemisinin-based Combination Therapy and Quinine on Treatment Failure and Resistance in Uncomplicated Malaria

Completed

All 16 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
16